Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren's syndrome

Signal Transduct Target Ther. 2022 Aug 29;7(1):274. doi: 10.1038/s41392-022-01103-x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artesunate
  • Glycolysis
  • Humans
  • Sjogren's Syndrome*
  • Th17 Cells*

Substances

  • Artesunate